Multiple Sclerosis
Conference Coverage
Relapsing-remitting MS best treated within 6 months of onset
BERLIN – Disease-modifying treatment for relapsing-remitting multiple sclerosis decreased the risk of disability progression at 12 months by 28...
Conference Coverage
Level of Serum Neurofilament Light Enables Treatment Monitoring
BERLIN—Serum neurofilament light chain (sNfL) levels are clinically relevant, and data suggest cut points to enable...
Conference Coverage
Mood disorders worsen multiple sclerosis disability
BERLIN – Men with MS and either depression or bipolar disorder were at especially higher risk of worsening disability.
Conference Coverage
Revamped MS criteria boost pediatric diagnoses
BERLIN – Oligoclonal bands and absence of anti-MoG antibodies are useful clinical markers during a diagnostic work-up.
Conference Coverage
No elevated cancer risk with MS therapies in COMBAT-MS data
BERLIN – No elevations were seen in overall cancer rates, or in breast cancer rates.
From the Journals
Virus-specific T-cell infusion may resolve progressive multifocal leukoencephalopathy
One patient fully recovered and a second improved but had speech and mobility problems.
From the Journals
Studies reveal pregnancy trends in American women with MS
Conference Coverage
Research highlights the use of neurofilament light chain as a biomarker
Follow #ECTRIMS2018 on Twitter to see live highlights and perspective from researchers and meeting attendees.
Conference Coverage
Revised McDonald criteria to be explored at ECTRIMS
The revised criteria should allow for earlier diagnosis and treatment of multiple sclerosis, but could be leading to overdiagnosis and...
Conference Coverage
Hot topic explores neuropathologic differences between MS individuals
Article
Multiple Sclerosis Journey
Partnering with patients on their journey.